The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 4, 2013, Pages 239-251

  Aldebasi, Yousef H ^a   Rahmani, Arshad H ^a   Khan, Amjad A ^a   Mesalhy Aly, Salah ^a,b  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Bladder cancer; Diabetic retinopathy; Progression; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1; NICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BLADDER CANCER; CANCER GROWTH; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; DIABETIC RETINOPATHY; DIABETOGENESIS; GENETIC VARIABILITY; HUMAN; HYPOXIA; LASER COAGULATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SMOKING; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR B GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR C GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR D GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

EID: 84877613151     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Madeb R and Meesing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22: 86-92.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Redelman S, Gil I, Gopa S, David BG and Michael S. Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells. Cancer Res 2013; 73: 1156-67.
4. Nanda MS, Sameer AS, Syeed N, Shah ZA, Murtaza I, Siddiqi MA, Ali A. Genetic aberrations of the K-RAS proto-oncogene in bladder cancer in Kashmiri population. Urol J 2010; 7: 168-173.
5. Rahmani A, Alzohairy M, Babiker AY, Rizvi MA, Elkarimahmad HG. Clinicopathological significance of PTEN and bcl2 expressions in oral squamous cell carcinoma. Int J Clin Exp Pathol 2012; 5: 965-971.
6. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP and Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006; 175: 1245-1252.
7. Rahmani A, Alzohairy M, Khadri H, Mandal AK, Rizvi MA. Expressional evaluation of Vascular Endothelial Growth Factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke. Int J Clin Exp Pathol 2012; 5: 195-202.
8. Nicosia RF, Zorzi P, Ligresti G, Morishita A and Alfred C. Aplin 2 Paracrine Regulation Of Angiogenesis By Different Cell Types In The Aorta Ring Model. Int J Dev Biol 1994; 55: 447-453.
9. Takahashi K and Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 2006; 126: 663-676.
10. Jouanneau J, Moens G, Bourgeois Y, Poupon MF and Thiery JP. A minority 01 carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc Nat Acad Sci 1994; 91: 286-290.
11. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 27: 1171-80.
12. Breier G. Angiogenesis in embryonic development-a review. Placenta 2000; 21: 11-15.
13. Daniel TO and Abrahamson D. Endothelial signal integration in vascular assembly. Ann Rev Physiol 2000; 62: 649-671.
14. Terman BI and Stoletov KV. VEGF and Tumor Angiogenesis. Einstein Quart J Biol and Med 2001; 18: 59-66.
15. Polverini PJ. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995; 6: 230-247.
16. Pandya NM, Dhalla NS and Santani DD. Angiogenesis--a new target for future therapy. Vascul Pharmacol 2006; 44: 265-274.
17. O'Brien T, Cranston D, Fuggle S, Bicknell R and Harris AL. Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer. Cancer Res 1995; 55: 510-513.
18. Gerber HP, Dixit V and Ferrara N. Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells. J Biol Chem1998; 273: 13313-13316.
19. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 1: 9-22.
20. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 18: 11947-54.
21. Claffey KP, Senger DR and Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995; 1246: 1-9.
22. Grimmond S, Lagercrantz J, Drinkwater C, Sillins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskjold M, Ward L, Hayward N, Weber G. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996; 6: 124-131.
23. Olofsson B, Pajusola K, von-Euler G, Chilov D, Alitalo K and Eriksson U. Genomic organization of the mouse and human genomes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice form. J Biol Chem 1996; 271: 19310-19317.
24. Lee RJ, Springer ML, Blanco-Bose WE and Shaw R. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
25. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Reviews in Oncol/Hematol 2007; 62: 179-213.
26. Li X, Liu B, Xiao J, Yuan Y, Ma J, Zhang Y. Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer. J Gastrointest Surg 2011; 15: 2001-2010.
27. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91: 125-132.
28. Yang J, Wu HF, Qian LX, Zhang W, Hua LX, Yu ML, Wang Z, Xu ZQ, Sui YG, Wang XR. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl 2006; 8: 169-175.
29. Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D, ou M. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011; 30: 14.
30. Guo X, Chen Y, Xu Z, Qian Y and Yu X. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 217-222.
31. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci 1998; 2: 548-553.
32. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N and Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997; 16: 3898-3911.
33. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Med 2001; 7: 186-191.
34. Yamada Y, Jo N, Shimane M and Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997; 42: 483-488.
35. Ortega N, Hutchings H, and Plouet J. Signal relays in the VEGF system. Front Biosci 1999; 4: 141-152.
36. Li X and Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001; 33: 421-426
37. Stuttfeld E and Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life 2009; 61: 915-22.
38. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258-268.
39. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
40. Jusila L and Alitalo K. Vascular growth factors and lymphangiogenesis (Review). Physiol Rev 2000; 82: 673-700.
41. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
42. Fischer C, Mazzone M, Jonckx B and Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8: 942-956.
43. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010; 140: 268-279.
44. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006; 119: 1519-1529.
45. Neil P, Fam NP, Verma S, Kutryk M and Stewart DJ. Clinician Guide to Angiogenesis. Circulatiom 2003; 108: 2613-2618.
46. Kabrun N, Buhring HJ, Choi K, Ullrich A, Risau W and Keller G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997; 124: 2039-2048.
47. Choi K, Kennedy M, Kazarov A, Papadimitriou JC and Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732.
48. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276: 3222-3230.
49. Jin KL, Mao XO and Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci 2000; 97: 10242-10247.
50. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, Madri JA, Ment LR. Paracrine and autocrine functions of neuronal VEGF in the CNS. J Biol Chem 2002; 277: 11410-11415.
51. Shiote M, Nagano I, Ilieva H, Murakami T, Narai H, Ohta Y, Nagata T, Shoji M, Abe K. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience 2005; 132: 175-182.
52. Yang K and Cepko CL. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 1996; 16: 6089-6099.
53. Lohela M, Saaristo A, Veikkola T and Alitalo K. Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost 2003; 90: 167-84.
54. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K. Signalling properties of FLT4, a proteolytically processedreceptor tyrosine kinase related to two VEGF receptors. Oncogene 1994; 9: 3545-55.
55. Takahashi H and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science 2005; 109: 227-241.
56. Tammela T, Enholm B, Alitalo K and Paavone K. The biology of vascular endothelial growth factors. Cardiovas Res 2005; 65: 550-563.
57. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc Natl Acad Sci 1995; 92: 35663570.
58. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 2087-2096.
59. Holmes K, Roberts OL, Thomas AM and Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007 Oct; 19: 2003-12.
60. Li B, Xu W, Luo C, Gozal D, Liu R. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 2003; 111: 155-64.
61. Isenovic ER, Meng Y, Divald A, Milivojevic N and Sowers JR. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells. Endocrine 2002; 19: 287-292.
62. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P. Role of PlGF in the intraand intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
63. Cunningham SA, Waxham MN, Arrate PM and Brock TA. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 1995; 270: 20254-20257.
64. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001; 276: 17686-17692.
65. Coffer PJ, Jin J and Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998; 335: 1-13.
66. Cantley LC and Neel BG. New insights into tumor suppression: PTEN suppression tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci 1999; 96: 4240-4245.
67. Di Cristofano A and Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
68. Tang JM, He QY, Guo RX and Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-191.
69. Maehama T and Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
70. Liekens S, Clercq ED and Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-270.
71. Mignatti P and Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117-137.
72. Pozzi A and Zent R. Regulation of endothelial cell functions by basement membraneand arachidonic acid-derived products. Wiley Interdiscip Rev Syst Biol Med 2009; 1: 254-272.
73. Lamalice L, Boeuf FL and Huot J. Endothelial cell migration during angiogenesis. Circulation Res 2007; 100: 782-794.
74. Bjorndahl M, Cao R, Eriksson A and Cao Y, Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circulation res 2004; 94: 1443-1450.
75. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N. Vascular endothelial growth factor is a secreted antiogenic mitogen. Science 1989; 246: 1306-1309.
76. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P and Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857.
77. Ribatti D, Vacca A and Dammacco F. The role of the vascular phase in solid tumor growth: A historical review. Neoplasia 1999; 1: 293-302.
78. Panovska J, Byrne HM, Maini PK. A theoretical study of the response of vascular tumours to different types of chemotherapy. Math Comp Mod 2008; 47: 560-579.
79. Chaplain MAJ. Avascular growth, angiogenesis and vascular growth in solid tumours: The mathematical modelling of the stages of tumour development. Mathematical and Computer Modelling 1996; 23: 47-87.
80. Klagsbrun M and D'Amore P. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270.
81. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
82. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008; 4: 241-246.
83. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73: 333-346.
84. Breier G, Licht AH, Nicolaus A, Klotzsche A, Wielockx B and Kirsnerova Z. HIF in vascular development and tumour angiogenesis. Novartis Found Symp 2007; 283: 126-133.
85. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
86. Ushio-Fukai M and Nakamura Y. Reactive Oxygen Species and Angiogenesis: NADPH Oxidase as Target for Cancer Therapy. Cancer Lett 2008; 266: 37-52.
87. Yasuda M, Ohzeki Y, Shimizu S, Naito S, Ohtsuru A, Yamamoto T and Kuroiwa Y. Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Life Sci 1999; 64: 249-258.
88. Bjorndahl M, Cao R, Eriksson A and Cao Y. Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion. Circulation Res 2004; 94: 1443-1450.
89. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular Endothelial Growth Factor/Vascular Permeability Factor Enhances Vascular Permeability Via Nitric Oxide and Prostacyclin. Circulation 1998; 97: 99-107.
90. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857.
91. Forster Y, Meye A, Krause S and Schwenzer B. Antisense-mediated VEGF suppression in bladder and breast cancer cells. Cancer Lett 2004; 20: 95-103.
92. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-8683.
93. Gupta K and Zhang J. Angiogenesis: a curse or cure? Postgrad Med J 2005; 81: 236-242.
94. Los M, Roodhart JLM and Voest EE. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. The Oncologist 2007; 12: 443-450.
95. Tesfaye S, Chaturvedi N, Eaton S, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR and Fuller JH. Vascular Risk Factors and Diabetic Neuropathy. N Engl J Med 2005; 352: 341-350.
96. Porta M and Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 2004; 103: 167-77.
97. Cao Y and Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286.
98. Albini A and Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7: 139-47.
99. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X and Jiang BH. Apigenin inhibits tumor angiogenesis through decreasing HIF-1α and VEGF expression. Carcinogenesis 2006; 28: 858-864.
100. Bhat TA and Singh RP. Tumor angiogenesisa potential target in cancer chemoprevention. Food Chem Toxicol 2008; 46: 1334-1345.
101. Lu J, Zhang K, Nam S, Anderson RA, Jove R and Wen W. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. Carcinogenesis 2010; 31: 481-488.
102. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T and Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-75.
103. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97-132.
104. Kowanetz M and Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12; 5018.
105. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK and DiPietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Inves 2008; 88: 579-590
106. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-1452.
107. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375-1379.
108. Wu Y, Zuo Y, Chakrabarti R, Feng B, Chen S and Chakrabarti S. ERK5 aontributes to VEGF alteration in diabetic retinopathy. J Ophthalmol 2010; 2010: 465824.
109. Bates DO and Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39: 225-37.
110. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, Beauchamp M, Checchin D, Hardy P, Sennlaub F, Lachapelle P and Chemtob S. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol 2010; 120: 51-60.
111. Sapieha PT, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS and Chemtob S. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010; 42: 5-12.
112. Xu L, Kanasaki K, Kitada M and Koya D. Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair 2012 Aug 1; 5: 13.
113. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H and Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch 1995; 426: 479-486.
114. Aiello LP, Northrup JM, Keyt BA, Takagi H and Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-1544.
115. Yan Q, Li Y, Hendrickson A and Sage EH. Regulation of retinal capillary cells by basic fibroblast growth factor, vascular endothelial growth factor, and hypoxia. In Vitro Cell Dev Biol Anim 2001; 37: 45-49.
116. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64: 505-517.
117. Donnelly R, Idris I and Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145-151.
118. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265: 783-793.
119. Young TA, Wang H, Munk S, Hammoudi DS, Young DS, Mandelcorn MS, Whiteside CI. Vascular endothelial growth factor expression and secretion by retinal pigment epithelial cells in high glucose and hypoxia is protein kinase Cdependent. Exp Eye Res 2005; 80: 651-662.
120. Kowluru RA. Diabetes-induced elevations in retinal oxidative estress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179-185.
121. Williamson JR, Chang K, Tilton RG, Prater C, Jeffrey JR, Weigel C, Sherman WR, Eades DM, Kilo C. Increased vascular permeability in spontaneously diabetic BB/W rats and rats with mild versus severe streptozocin-induced diabetes. Diabetes 1987; 36: 813-821.
122. Oliver JA. Adenylate cyclase and protein kinase C mediate opposite actions on endothelial junctions. J Cell Physiol 1990; 145: 536-542.
123. Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM and Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 1990; 85: 1991-1998.
124. Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR and Turk J. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 1991; 87: 31-38.
125. Werth DK, Niedel JE and Vinculin IP. A cytoskeletal substrate of protein kinase C. J Biol Chem 1983; 258: 11423-11426.
126. Stasek JE, Patterson CE and Garcia JGN. Protein kinase C phosphorylates caldesmon and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol 1992; 153: 62-75.
127. Xia P, Feener EP and King GL. Elevated glucose level regulates epidermal growth factor receptor (EGF-R) in aortic smooth muscle cells overexpressing protein kinase C. Diabetes 1994.
128. Pfeiffer A and Schatz H. Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 1995; 103: 7-14.
129. Katsura Y, Okano T, Noritake M, Kosano H, Nishigori H, Kado S, Matsuoka T. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Diabetes Care 1998; 21: 1759-1763.
130. Evcimen ND and King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55: 498-510.
131. Jiang BH and Liu LZ. Role of mTOR in anticancer drug resistance. Drug Resist Updat 2008; 11: 63-76.
132. Cantley LC and Neel BG. New insights into tumor suppression: PTEN Suppresses tumor formation by restraining academy the phosphoinositide 3-kinase/AKT pathway. Proc Nat Sci USA 1999; 96: 4240-4245.
133. Tamura M, Gu J, Matsumoto K, Aota SI, Parsons R and Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-1617.
134. Rodriguez S, Huynh-Do U. The Role of PTEN in Tumor Angiogenesis. J Oncol 2012; 2012: 141236.
135. Angelo LS and Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007; 15: 2825.
136. Huovinen R, Warri A and Collan Y. Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 1993; 55: 685-691.
137. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG and Benedict WF. Elevated and absent prb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res March 1998; 15: 1090.
138. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A and Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82: 161-166.
139. Anna M, Puzio-Kuter, Castillo-Martin M, Carolyn W, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and Abate-Shen C. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes and Dev 2009; 23: 675-680.
140. Fielding S, Short C, Davies K, Wald N, Bridges BA and Waters R. Studies on the ability of smoke from different types of cigarettes to induce DNA single-strand breaks in cultured human cells. Mutat Res 1989; 214: 147-151.
141. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994 Dec; 74: 762-6.
142. Bochner B, Cote R, Groshen S, Esrig D, Freeman J, Weidner N, Chen SC, Skinner D and Nichols P. Angiogenesis in bladder cancer: relationship between microvessel density and tumour prognosis. J Natl Cancer Inst 1995; 87: 1603-1612.
143. Ferrara N and Davis-Smyth TD. The biology of vascular endothelial growth factor. Endocr Rev 1997; 10: 4-25.
144. Wang S, Xia T, Zhang Z, Kong X, Zeng L, Mi P, Xue Z. Expression of VEGF and tumor angiogenesis in bladder. Zhonghua Wai Ke Za Zhi 2000; 38: 34-6.